Work

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Year: 2014

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-014-2615-5

Authors: Anthony W. Tolcher, Amita Patnaik, Kyriakos P. Papadopoulos, Drew W. Rasco, Carlos R. Becerra, Alicia J. Allred, Keith Orford, Gursel Aktan, Geraldine Ferron-Brady, Nageatte Ibrahim, Jennifer Gauvin, Monica Motwani, Mark Cornfeld

Institutions: South Texas Accelerated Research Therapeutics, Texas Oncology, GlaxoSmithKline (United Kingdom), GlaxoSmithKline (United States)

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Institutes of Health, U.S. Food and Drug Administration

OpenAlex ID: W1992880310

FWCI: 4.511

Cites: 15

Cited by: 156

Related to: 10